LEXINGTON, Mass.— N-of-One, Inc., the leading provider of molecular interpretation for personalized medicine in cancer, today announced that it has launched Variant InterpreterTM on Illumina’s BaseSpace Apps, Illumina’s dedicated applications store and informatics community dedicated to advancing genomic analysis.

The Variant InterpreterTM app, which is cloud based, allows oncologists and researchers to access relevant biological and clinical knowledge and insights related to the mutation profile of a tumor identified by targeted sequencing. Initial release will cover 30 prevalent cancer associated genes that are commonly tested. Future releases will include additional genes. This app links the results of sequencing to published cutting-edge, disease-specific research and analysis of cancer.

“N-of-One unleashes the power of next generation sequencing (NGS) for oncologists, pathologists and researchers by providing the latest published clinical and scientific knowledge associated with NGS data from each tumor,” said Chris Cournoyer, Chief Executive Officer of N-of-One. “Variant InterpreterTM is N-of-One’s first app in the cloud, demonstrating that our services and content can be deployed in a variety of ways to meet evolving markets needs. We plan on introducing other apps in conjunction with Illumina’s evolving portfolio.

Using this app, oncologists, pathologists and researchers can quickly request a molecular interpretation of a variant or multiple variants in a tumor using convenient drop-down menus in a familiar app format, and rapidly receive a customized interpretative roadmap linking the variant data to scientific knowledge.

To use the Variant Interpreter app, the user selects a tumor type plus one or more variants to be interpreted from the drop-down menus. Also for each variant, N-of-One supplies a summary on the effect of the variant, incidence of mutations in this tumor type and the role this mutation may play in the tumor.

Informatics solutions available through BaseSpace Apps allow customers to utilize the tools from a growing community of academic, commercial, and open source providers.

About N-of-One

N-of-One, a leader in precision medicine, leverages its world-class team of experts to translate molecular data specific to each patient into state-of-the-art, clinically actionable insights and therapeutic options focused on the point of care. Using the company’s PrecisionWorks™ knowledge integration platform and framework, N-of-One’s team of experts has delivered more than 6,000 personalized, interpretative roadmaps to oncologists and patients worldwide, through partnerships to provide interpretation services for leading diagnostic companies (such as Foundation Medicine and Clarient), through agreements with provider networks (such as Fox Chase Cancer Center in Philadelphia), directly to oncologists or through employee access benefit programs (such as Life Technologies). N-of-One does not provide medical advice or promote any product or service. For more information, please visit www.n-of-one.com or call 617-202-9808.